Journal of Clinical Investigation,
Год журнала:
2025,
Номер
135(3)
Опубликована: Фев. 2, 2025
Preclinical
and
clinical
observations
indicate
that
the
probiotic
Lactobacillus
rhamnosus
GG
(LGG)
can
modulate
colonic
inflammation.
However,
underlying
mechanisms
have
not
been
explored
in
depth.
Here,
we
demonstrate
oral
administration
of
live
LGG
alleviated
inflammatory
colitis
by
increasing
IL-10
expression
intestinal
Ly6C+
monocytes.
Mechanistically,
induced
production
via
stimulator
IFN
genes
(STING)/TBK1/NF-κB
(RELA)
signaling
pathway
monocytes,
enhancing
their
immune-suppressive
function.
Elevated
subsequently
activated
resulting
an
IL-10-based
autocrine
regulatory
loop
inhibition
proinflammatory
cytokine
production.
Furthermore,
shifted
gut
microbial
community
its
metabolic
functions,
leading
to
immune
responses
against
colitis.
Fecal
microbiota
transplantation
from
LGG-colonized
mice
checkpoint
blockade-associated
Our
findings
highlight
importance
STING
IL-10-dependent
antiinflammatory
immunity
establish
empirical
basis
for
developing
as
efficient
safe
therapeutic
strategy
European Heart Journal,
Год журнала:
2022,
Номер
43(41), С. 4229 - 4361
Опубликована: Авг. 26, 2022
65-74
years,
Sex
category
(female)
CIED
Cardiac
implantable
electronic
device
CML
Chronic
myeloid
leukaemia
CMR
magnetic
resonance
COMPASS-CAT
Prospective
COmparison
of
Methods
for
thromboembolic
Journal of Clinical Oncology,
Год журнала:
2022,
Номер
41(2), С. 212 - 221
Опубликована: Сен. 1, 2022
Limited
prospective
data
are
available
on
sequential
immunotherapy
and
BRAF/MEK
inhibition
for
BRAFV600-mutant
metastatic
melanoma.SECOMBIT
is
a
randomized,
three-arm,
noncomparative
phase
II
trial
(ClinicalTrials.gov
identifier:
NCT02631447).
Patients
with
untreated,
melanoma
from
37
sites
in
nine
countries
were
randomly
assigned
to
arm
A
(encorafenib
[450
mg
orally
once
daily]
plus
binimetinib
[45
twice
until
progressive
disease
[PD]
->
ipilimumab
nivolumab
[ipilimumab
3
mg/kg
every
weeks
1
×
four
cycles
2
weeks]),
B
PD
encorafenib
binimetinib],
or
C
8
binimetinib).
The
primary
end
point
was
overall
survival
(OS)
at
years.
Secondary
points
included
total
progression-free
survival,
3-year
OS,
best
response
rate,
duration
of
response,
biomarkers
the
intent-to-treat
population.
Safety
analyzed
throughout
treatment
all
participants
who
received
least
one
dose
study
medication.A
209
patients
(69
A,
71
B,
69
C).
At
median
follow-up
32.2
(interquartile
range,
27.9-41.6)
months,
OS
not
reached
any
more
than
30
alive
arms.
Assuming
null
hypothesis
≤
15
met
2-year
rates
65%
(95%
CI,
54
76)
54%
41
67)
73%
62
84)
62%
48
69%
59
80)
60%
58
72)
C.
No
new
safety
signals
emerged.Sequential
targeted
therapy
provide
clinically
meaningful
benefits
melanoma.
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Май 25, 2023
Since
the
first
Immune
Checkpoint
Inhibitor
was
developed,
tumor
immunotherapy
has
entered
a
new
era,
and
response
rate
survival
of
many
cancers
have
also
been
improved.
Despite
success
immune
checkpoint
inhibitors,
resistance
limits
number
patients
who
can
achieve
lasting
response,
immune-related
adverse
events
complicate
treatment.
The
mechanism
(irAEs)
is
unclear.
We
summarize
discuss
mechanisms
action
different
types
their
possible
mechanisms,
describe
strategies
targets
for
prevention
therapeutic
interventions
to
mitigate
them.
ESMO Open,
Год журнала:
2022,
Номер
7(2), С. 100404 - 100404
Опубликована: Фев. 24, 2022
•There
is
a
lack
of
guidance
for
the
management
DIILD
in
cancer
patients.•A
multidisciplinary
team
Italy
developed
step-by-step
diagnostic
and
therapeutic
guidelines
patients.•Differential
diagnosis
critical
to
exclude
other
forms
interstitial
lung
disease
or
infectious
causes.•Usually
antineoplastic
agent
discontinued,
steroids
started
further
dictated
by
severity.
BackgroundDrug-induced
(DIILD)
form
resulting
from
exposure
drugs
causing
inflammation
possibly
fibrosis.
Antineoplastic
are
primary
cause
DIILD,
accounting
23%-51%
cases,
with
bleomycin,
everolimus,
erlotinib,
trastuzumab-deruxtecan
immune
checkpoint
inhibitors
being
most
common
causative
agents.
can
be
difficult
identify
manage,
there
currently
no
specific
on
treatment
caused
anticancer
drugs.ObjectiveTo
develop
recommendations
patients.MethodsBased
published
literature
their
clinical
expertise,
group
experts
stratified
severity,
based
Common
Terminology
Criteria
Adverse
Events.ResultsThe
highlight
importance
interaction
DIILD.
Important
components
process
physical
examination
careful
patient
history-taking,
measurement
vital
signs
(particularly
respiratory
rate
arterial
oxygen
saturation),
relevant
laboratory
tests,
function
testing
spirometry
diffusing
capacity
carbon
monoxide
computed
tomography/imaging.
Because
radiological
often
similar
those
pneumonias
diseases,
differential
important,
including
microbial
serological
confirm
causes.
In
requires
discontinuation
administration
short-term
steroids.
Steroid
tapering
must
undertaken
slowly
prevent
reactivation
Patients
severe
very
(grade
3
4)
will
require
hospitalisation
need
non-invasive
ventilation.
Decisions
about
invasive
ventilation
should
take
into
account
patient’s
prognosis.ConclusionsThese
provide
structured
approach
each
grade
suspected
cancer-related
Drug-induced
drugs.
To
patients.
Based
Events.
The
prognosis.
These
